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To determine whether fluoroquinolone exposure is a
risk factor for the isolation of Staphylococcus aureus and
whether the effect is different for methicillin-resistant S.
aureus (MRSA) versus methicillin-susceptible S. aureus
(MSSA), we studied two case groups. The first case group
included 222 patients with nosocomially acquired MRSA.
The second case group included 163 patients with nosoco-
mially acquired MSSA. A total of 343 patients admitted con-
currently served as controls. Outcome measures were the
adjusted odds ratio (OR) for isolation of MRSA and MSSA
after fluoroquinolone exposure. Exposure to both lev-
ofloxacin (OR 5.4; p < 0.0001) and ciprofloxacin (OR 2.2; p
< 0.003) was associated with isolation of MRSA but not
MSSA. After adjustment for multiple variables, both drugs
remained risk factors for MRSA (levofloxacin OR 3.4; p <
0.0001; ciprofloxacin OR 2.5; p = 0.005) but not MSSA.
Exposure to levofloxacin or ciprofloxacin is a significant risk
factor for the isolation of MRSA, but not MSSA. 
M
ethicillin-resistant  Staphylococcus aureus (MRSA)
has been implicated as a pathogen in hospital-
acquired infections since the 1960s (1). During the 1990s,
the proportion of nosocomial infections caused by MRSA
increased substantially, and MRSA is now a leading cause
of such infections in the United States (2). According to
data from the SENTRY Antimicrobial Surveillance
Program, approximately 40% of S. aureus isolates recov-
ered in intensive care units (ICU) are resistant to methi-
cillin (3). Recently, MRSAinfections acquired in the com-
munity have been identified as emerging pathogens
responsible for substantial disease and death (4,5). While
no satisfactory explanation exists for the recent prolifera-
tion of MRSA, expanded use of antimicrobial drugs in
sites outside the hospital has been suggested as a major
contributor to emerging resistance in the community (6).
Fluoroquinolones are among the most commonly pre-
scribed classes of antimicrobial drugs in both the hospital
and in the community. Ciprofloxacin, one of the first fluo-
roquinolones to gain extensive clinical use, was originally
heralded for its activity against a broad range of pathogens,
including MRSA (7). However, by the early 1990s, many
MRSA isolates from clinical specimens were found to be
resistant to ciprofloxacin (8). The next generation of fluo-
roquinolones, including levofloxacin, was introduced dur-
ing the second part of the 1990s and promised improved
activity against gram-positive pathogens. Unfortunately,
screening of large numbers of staphylococcal bloodstream
isolates as part of the SENTRYAntimicrobial Surveillance
Program demonstrated resistance to many of the newest
fluoroquinolones as well (9). 
Several recent investigations offer preliminary evi-
dence that suggests that the fluoroquinolones themselves
may actually predispose patients to infection with or car-
riage of MRSA. A comparison of microbiology laboratory
data with antimicrobial reimbursement reports found a sig-
nificant correlation between ciprofloxacin prescriptions
and the isolation of MRSA (10). Two case-control studies
examining risk factors for MRSA have found a significant
association between fluoroquinolone exposure and MRSA
isolation or infection (11,12). Preliminary analysis from
one also suggested a difference in risk between members
of the class. Additionally, a prospective study examining
the impact of nasally administered mupirocin ointment on
MRSA carriage also identified fluoroquinolone exposure
as a risk factor for MRSA carriage (13). However, none of
these studies was designed specifically to examine the risk
associated with fluoroquinolones. Moreover, the design of
the prior case-control investigations, as a result of the inap-
propriate use of patients colonized or infected with sensi-
tive strains for controls, may have yielded biased results.
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This study was specifically designed to determine
whether exposure to fluoroquinolones is a risk factor for
the subsequent isolation of S. aureus, and whether the
effect is different for MRSAversus methicillin-susceptible
S. aureus (MSSA). In addition, we sought to preliminarily
explore any difference in risk between levofloxacin and
ciprofloxacin. 
Methods
The study was performed at the Beth Israel Deaconess
Medical Center, a 640-bed tertiary care teaching hospital
in Boston, Massachusetts. The case-case-control method
was used. As originally described by Kaye et al., this tech-
nique more rigorously upholds the epidemiologic standard
that membersof a control group be selected independently
of their exposure status (14,15). A number of subsequent
studies and commentary have upheld the utility of this
method as providing the most accurate estimates of risk in
studies of antimicrobial drug resistance (15–21). The case-
case-control design is actually composed of two parallel
case-control studies. Here, the first group of cases consist-
ed of patients from whom nosocomially acquired MRSA
was isolated. The second case group was comprised of
patients from whom nosocomially acquired MSSA was
recovered. S. aureus isolates were identified by using stan-
dard laboratory procedures. Resistance was determined
according to the National Committee for Clinical
Laboratory Standards guidelines with automated microdi-
lution testing with the VITEK 2 system (bioMérieux,
Hazelwood, MO). In addition, oxacillin resistance was
confirmed on MRSAscreening agar. Amicrobiology labo-
ratory database of clinical cultures was searched to identi-
fy patients from whom S. aureus was isolated from
November 1, 1999, to August 1, 2001. Any patient from
whom S. aureus was first recovered during the initial 72
hours after admission to the medical, surgical, or obstetric
services was presumed to have acquired the organism
before hospitalization and was excluded. The control
group for each of the two component studies was com-
posed of a computer-generated random sample of patients
admitted during the same period to the medical, surgical,
or obstetric services from whom S. aureus was not isolat-
ed. To be included, control patients needed to be hospital-
ized for at least 72 hours. The same group of control
patients was used for both cases with MRSA and MSSA. 
Data regarding candidate risk factors were collected
from existing administrative, pharmacy, and laboratory
databases by using a relational database management sys-
tem (Access; Microsoft Corporation, Redmond, WA). In
addition to patient sex and age, coexisting medical condi-
tions were analyzed; these included the presence or
absence of cardiovascular, lung, hepatic or renal disease;
previous organ transplant; AIDS; malignancy; and diabetes
mellitus. Factors specifically relating to hospitalization
were collected and analyzed, including transfer from
another hospital or care facility, prior surgical procedure or
ICU stay, presence or absence of intravenous line, emer-
gent admission, admission service (medicine, surgery, or
obstetrics), and the number of days at risk for infection.
For case-patients, the last was equal to the number of days
of hospitalization before the first isolation of S. aureus. For
control patients, the number of days at risk was defined as
the total length of stay. While the primary objective was to
measure the specific risk associated with exposure to lev-
ofloxacin or ciprofloxacin, also considered was exposure
to a number of other antimicrobial agents, including van-
comycin, penicillins, β-lactam/β-lactamase inhibitor com-
binations, first- and second-generation cephalosporins,
third-generation cephalosporins, carbapenems, clin-
damycin, and metronidazole. During the study period, lev-
ofloxacin and ciprofloxacin were the only fluoro-
quinolones used routinely at the Beth Israel Deaconess
Medical Center. To be included as an exposure, any
antimicrobial drug dosing, surgical procedure, ICU stay,
and placement of intravenous line had to occur before the
isolation of S. aureus in case-patients.
According to the hospital’s infection-control policy, all
patients from whom MRSA is isolated are placed on con-
tact precautions in a private room. In addition, patients
from whom resistant bacteria have been isolated during
prior hospitalizations are automatically flagged and isolat-
ed at the time of readmission to minimize cross-contami-
nation. Appropriate adherence to these policies by the staff
is consistent across different care units. During the study
period, patients diagnosed with MRSA infection were
treated with vancomycin.
The SAS software package (SAS Institute, Cary, NC)
was used for all statistical analysis. Because the opportuni-
ty for both exposures and outcome (i.e., a clinical culture
positive for S. aureus) would necessarily increase with the
number of days at risk, simple univariate analysis does not
appropriately reflect the individual risk associated with
each of the candidate risk factors. Therefore, a two-vari-
able logistic regression model adjusted for time at risk was
used to specify the individual risk associated with lev-
ofloxacin, ciprofloxacin, and each of the other candidate
risk factors. Odds ratios (OR), 95% confidence intervals
(CI), and p values were calculated for each.
To quantify more accurately the specific risk for S.
aureus isolation after exposure to levofloxacin or
ciprofloxacin, variables with a p value of <0.05 in the
adjusted univariate analysis were included in a logistic
regression model along with each of the fluoroquinolones.
Separate models were constructed for MRSA and MSSA
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Candidate risk factors that reached statistical significance
(p < 0.05) were retained in the multivariable model to
adjust the risk associated with levofloxacin and
ciprofloxacin. For each of the two case groups, candidate
risk factors that did not reach statistical significance in the
multivariable model were only allowed to remain in the
model as confounders if their removal changed the coeffi-
cient for levofloxacin or ciprofloxacin by >10%.
Interaction terms for each of the risk factors included in the
final model were similarly included if these criteria were
met. Each of the final multivariable models was tested for
overfitting by using the bootstrap method (1,000 bootstrap
samples of all of the data). Goodness-of-fit of the final
models was evaluated with the Hosmer-Lemeshow test.
The project was approved by the institutional review board
of the Beth Israel Deaconess Medical Center
Results
Two hundred twenty-two patients with nosocomial
MRSA and 163 with nosocomial MSSA were identified
and served as the two case groups. For both, 343 random-
ly selected inpatients hospitalized for at least 72 hours
were identified as controls. The mean age of MRSA and
MSSAcases was 66.2 and 63.3 years, respectively. Control
patients, with a mean age of 57.6 years, were significantly
younger. Compared to 39.9% of controls, 56.8% of MRSA
patients and 55.8% of MSSApatients were men. The mean
number of days in hospital before the first positive culture
was 12.4 and 7.7 for MRSA and MSSA patients, respec-
tively. In comparison, the number of days at risk for con-
trol patients was 6.7 days, significantly shorter than for
those from whom resistant organisms were isolated. In
total, 67.6% of the MRSA patients were exposed to one of
the two fluoroquinolones under study. This value was sig-
nificantly greater than the number for MSSA (22.7%) or
control (21.0%) patients. Of all MRSAisolated, 97% were
resistant to fluoroquinolones as opposed to 8% of MSSA
strains. As described elsewhere, approximately 80% of
isolates tested were variants of a single pulsed-field gel
electrophoresis type (22). In addition, during the study, no
epidemiologically related outbreak of S. aureus disease
was detected at the institution.
MRSA Versus Control Patients
The results of univariate analyses for MRSA adjusted
for days at risk are shown in Table 1. Exposure to both lev-
ofloxacin (OR 5.4; p < 0.0001) and ciprofloxacin (OR 2.2;
p = 0.0027) was more common among MRSAcase-patients
than controls. In addition, male patients were more likely to
be case-patients than controls (OR = 1.8; p = 0.014). When
compared with patients <50 years of age, those 50–75 years
of age (OR = 2.4; p < 0.0001) and >75 years of age (OR =
2.9; p < 0.001) were more likely to be cases. Cardiovascular
(OR 1.8; p = 0.0043), lung (OR 6.8; p < 0.0001), renal (OR
2.0; p = 0.0114), and hepatic (OR 2.4; p = 0.0107) disease
were all more common among cases than controls. Hospital
transfer (OR 2.9; p < 0.0001), ICU stay (OR 7.7; p <
0.0001), intravenous line (OR 2.1; p = 0.0008), and emer-
gency room admission (OR 2.2; p < 0.0001) were also sig-
nificantly more frequent among case-patients than controls.
Patients admitted to the obstetrics service, when compared
with those admitted to the medical service, were more like-
ly to be controls than case-patients (OR 0.1; p < 0.0001). In
addition to the fluoroquinolones, exposure to several other
antimicrobial drugs was significantly more common among
cases than controls, including vancomycin (OR 4.0; p <
0.0001), penicillin (OR 2.1; p = 0.0042), third-generation
cephalosporins (OR 3.7; p < 0.0001), clindamycin (OR 5.4;
p < 0.0001), and metronidazole (OR 4.2; p < 0.0001). 
Multivariable models to quantify the specific risk asso-
ciated with levofloxacin or ciprofloxacin were constructed
for MRSA cases. The results are shown in Table 2. After
adjustment for other significant and confounding vari-
ables, including other antibiotic exposures, exposure to
either levofloxacin (OR 3.4; p = 0.0001) or ciprofloxacin
(OR 2.5; p = 0.0049) was more common among MRSA
cases than controls. No interaction terms met the signifi-
cance criteria for inclusion in the final model.
MSSA Versus Control Patients
The results of univariate analyses adjusted for days at
risk for MSSAare shown in Table 3. As opposed to the sit-
uation for those with MRSA, MSSA cases were no more
likely than controls to have been exposed to levofloxacin
or ciprofloxacin. MSSA case-patients were more likely
than controls to be male (OR 1.9; p = 0.0011). Patients >75
years old were more likely than those <50 to be case-
patients (OR 2.1; p = 0.0037). Some coexisting conditions
were more common among case-patients than controls,
including cardiovascular (OR 2.1; p = 0.0004), lung (OR
3.0; p < 0.0001), renal (OR 2.1; p = 0.0119), and hepatic
disease (OR 3.2; p = 0.0006). Hospital transfer (OR 2.1; p
= 0.0076), ICU stay (OR 6.4; p < 0.0001), intravenous line
(OR 2.0; p = 0.0023), and emergency room admission (OR
2.0; p = 0.0009) were also more likely among case-patients
than controls. When compared with patients admitted to
the medical service, those admitted to the surgical service
were more likely to be cases (OR 1.5; p = 0.0497), and
those admitted to obstetrics were more likely to be controls
(OR 0.1; p = 0.0002). Among antimicrobial agents, only
exposure to penicillin (OR 2.2; p = 0.0039) and metronida-
zole (OR 1.7; p = 0.043) was more frequent among cases
than controls.
The results for the multivariable models quantifying the
specific risk for MSSA associated with levofloxacin or
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in Table 2. In contrast to the findings for MRSA, MSSA
case-patients were not significantly more likely to have
previously received levofloxacin (OR 0.7; p = 0.3023) and
tended to have a smaller risk of having received
ciprofloxacin (OR 0.5; p = 0.0571) than the controls. 
Effects of Fluoroquinolone Exposure 
on MRSA and MSSA
In this study, patients from whom nosocomially
acquired MRSA was isolated were approximately three
times as likely as those with MSSA to have received prior
therapy with levofloxacin or ciprofloxacin (67.6% vs.
22.7%). Adjusting for time at risk, MRSA isolation and
prior exposure to both levofloxacin (OR 5.4; p < 0.0001)
and ciprofloxacin (OR 2.2; p = 0.0027) were associated.
For MSSA, the association was not significant for either
levofloxacin (OR 1.1; p = 0.77) or ciprofloxacin (OR 0.74;
p = 0.37). After adjusting for multiple risk factors, includ-
ing exposure to other antimicrobial classes, exposures to
levofloxacin (OR 3.4; p < 0.0001) and to somewhat lesser
degree ciprofloxacin (OR 2.5; p = 0.0049) were significant-
ly associated with MRSA. For MSSAcases, exposure tend-
ed to be protective for ciprofloxacin (OR 0.5; p = 0.0571),
but not for levofloxacin (OR 0.7; p = 0.3023) (Figure).
Discussion
This case-case control study is the first specifically
designed to examine the epidemiologic link between fluo-
roquinolone exposure and the subsequent isolation of S.
aureus and to specifically differentiate between MRSA
and MSSA. After controlling for possible confounders,
including exposure to other antimicrobial agents, the
results reported here demonstrate a highly significant asso-
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Table 1. Results of univariate analysis for MRSA cases and controls  
Uncolonized (n = 343)  MRSA cases (n = 222)   
Risk factor  no.  %  no.  %  OR (95% CI)  p value 
Demographic             
Male  137  39.9  126  56.8  1.84 (1.27 to 2.67)  0.001 
Age  mean = 57.6 y  mean = 66.2 y    <0.001 
<50  131  38.2  39  17.6  —  — 
51–75  137  39.9  110  49.5  2.39 (1.50 to 3.83)  <0.001 
>75  75  21.9  73  32.9  2.86 (1.70 to 4.79)  <0.001 
Coexisting condition             
Cardiovascular disease  186  54.2  156  70.3  1.77 (1.20 to 2.31)  0.004 
Lung disease  57  16.6  130  58.6  6.74 (4.43 to 10.26)  <0.001 
Renal disease  30  8.7  46  20.7  2.02 (1.17 to 3.47)  0.01 
Hepatic disease  17  5.0  28  12.6  2.43 (1.23 to 4.79)  0.01 
Organ transplant  4  1.2  2  0.9  0.52 (0.08 to 3.36)  0.49 
AIDS  5  1.5  4  1.8  1.25 (0.30 to 5.14)  0.76 
Malignancy  54  15.7  32  14.4  0.98 (0.59 to 1.64)  0.94 
Diabetes mellitus  67  19.5  56  25.2  1.26 (0.81 to 1.96)  0.31 
Hospital factors             
Transfer  32  9.3  53  23.9  2.88 (1.71 to 4.83)  <0.001 
Surgical procedure  148  43.1  96  43.2  0.74 (0.51 to 1.09)  0.12 
ICU stay  54  15.7  144  64.9  7.66 (5.01 to 11.71)  <0.001 
Intravenous line  59  17.2  80  36.0  2.06 (1.38 to 3.16)  <0.001 
Emergent admission  149  43.4  136  61.3  2.20 (1.51 to 3.21)  <0.001 
Admission service             
Medical  174  50.7  154  69.4  —  — 
Obstetrical  62  18.1  2  0.9  0.05 (0.01 to 0.21)  <0.001 
Surgical   107  31.2  66  29.7  0.74 (0.49 to 1.10)  0.14 
Antimicrobial drugs             
Any fluoroquinolone   72  21.0  150  67.6  5.41 (3.60 to 8.11)  <0.001 
Levofloxacin  42  12.2  109  49.1  5.36 (3.45 to 8.32)  <0.001 
Ciprofloxacin  34  9.9  62  27.9  2.16 (1.31 to 3.56)  0.002 
Vancomycin  36  10.5  94  42.3  3.98 (2.49 to 6.34)  <0.001 
Penicillin  36  10.5  56  25.2  2.08 (1.26 to 3.45)  0.004 
β-lactam and inhibitor  5  1.5  13  5.9  2.74 (0.88 to 8.46)  0.08 
First-generation cephalosporin  77  22.4  45  20.3  0.77 (0.49 to 1.21)  0.25 
Third-generation cephalosporin  28  8.2  74  33.3  3.66 (2.18 to 6.13)  <0.001 
Carbapenem  3  0.9  7  3.2  1.63 (0.37 to 7.10)  0.52 
Clindamycin  9  2.6  32  14.4  5.36 (2.39 to 12.01)  <0.001 
Metronidazole  42  12.2  104  46.8  4.20 (2.70 to 6.55)  <0.001 
aAll results adjusted for time at risk. MRSA, methicillin-resistant Staphylococcus aureus; OR, odds ratio; CI, confidence interval; ICU, intensive care unit. ciation between treatment with levofloxacin or
ciprofloxacin and subsequent isolation of MRSA, but not
MSSA. The magnitude of the risk is less than reported in
earlier studies that did not examine this specific question
and whose design would tend to bias results. 
Substantial variability exists between both case groups
and controls with respect to a number of characteristics,
including coexisting illnesses, days spent in intensive care,
and presence of intravascular catheters. However, such dif-
ferences, several of which reflect variation in severity of
illness and immune status between the groups, do not neg-
atively affect the interpretation of the results. In fact, such
dissimilarity, familiar to clinicians, mirrors the very real
differences that exist between colonized or infected and
uncolonized patients. Because the same control group is
employed for both MRSA and MSSA patients, the case-
case-control method accounts for any potential confound-
ing attributable to these differences. Moreover, the sus-
tained association between fluoroquinolone exposure and
MRSA after adjusting for these surrogates of disease
severity and host immune status in the multivariable model
further supports the relationship. This conclusion was test-
ed in the handling of patients from the obstetrics service. A
priori, we elected to include both cases and controls from
the obstetric service. However since this patient population
contributed a significantly larger proportion to the control
group (18.1%) than to each of the case groups (0.9% and
1.8%), we performed a subgroup analysis to confirm the
aforementioned interpretation. When the subgroup analy-
sis was performed excluding patients from the obstetrics
service, the overall results of the study were not signifi-
cantly changed. 
Even in the face of intense selection pressure from
exposure to antimicrobial drugs, MSSA isolates very
rarely develop methicillin resistance. Therefore, any rela-
tionship between fluoroquinolones and MRSA probably
occurs at the level of host colonization. With this in mind,
the findings could be attributed to a number of etiologic
mechanisms. 
By eradicating the generally susceptible microorgan-
isms that colonize the skin and mucus membranes (e.g.,
nares, perirectal area), fluoroquinolone exposure effective-
ly opens an ecologic niche, rendering an inpatient vulner-
able to subsequent colonization and infection by the more
resistant strains endemic in the hospital, including MRSA.
Because fluoroquinolone resistance is relatively rare
among strains of MSSA while MRSA isolates tend to be
resistant (23), the net result could be the replacement of
MSSA with MRSA after fluoroquinolone exposure. 
Using in vitro analysis, Venezia et al. performed popu-
lation analysis on fluoroquinolone-susceptible, mecA-pos-
itive methicillin-heteroresistant strains of S. aureus.
Growth in the presence of 0.5 MIC of a fluoroquinolone
(ciprofloxacin, levofloxacin, moxifloxacin, or gati-
floxacin) resulted in a >10-fold increase in the proportion
of the population that grew on high concentrations of
oxacillin. The increase was directly proportional to the
concentration of the fluoroquinolone and could be detect-
ed within 8 hours of exposure. The authors conclude that
fluoroquinolones might influence oxacillin resistance by
selective inhibition or killing more susceptible subpopula-
tions of heteroresistant S. aureus. The surviving subpopu-
lations are more resistant to both oxacillin and the
quinolones (24). 
While plausible, neither of the first two explanations is
completely supported by the results of our study. Were the
relationship between fluoroquinolones and MRSA solely
attributable to selective pressure that favors the acquisi-
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Table 2. Results of multivariable analysis  
MRSA cases  MSSA cases 
Risk factor  OR (95% CI)  p value  OR (95% CI)  p value 
Primary covariates         
Levofloxacin  3.38 (1.94 to 5.90)  <0.001  0.69 (0.34 to 1.40)  0.30 
Ciprofloxacin  2.48 (1.32 to 4.67)  0.005  0.47 (0.21 to 1.02)  0.06 
Other covariates         
Lung disease  3.94 (2.43to6.40)  <0.001  2.33 (1.43 to 3.81)  <0.001 
Renal disease  *    1.98 (1.03 to 3.80)  0.04 
Penicillin  *    1.78 (0.93 to 3.39)  0.08 
Metronidazole  1.92 (1.10 to 3.37)  0.02  1.29 (0.65 to 2.56)  0.46 
ICU stay  5.33 (3.28 to 8.68)  <0.001  4.60 (2.90 to 7.30)  <0.001 
Emergent admission  1.74 (1.09 to 2.78)  0.02  1.90 (1.17 to 3.08)  0.01 
Admission service         
Medical  *    —  — 
Obstetrical  *    0.29 (0.08 to 1.05)  0.06 
Surgical  *    1.82 (1.12 to 2.97)  0.02 
aAll results adjusted for time at risk. Only variables significant (p < 0.05) on univariate analysis were included in final models. Several variables (indicated with an asterisk)
met criteria for inclusion in the MSSA (methicillin-susceptible Staphylococcus aureus), but not the MRSA (methicillin-resistant Staphylococcus aureus) model. OR, odds 
ratio; CI, confidence interval; ICU, intensive care unit. tion or emergence of fluoroquinolone-resistant strains, the
same phenomenon would be expected to apply with other
antimicrobial agents to which MRSA are also resistant.
For example, first-generation cephalosporins have activi-
ty against most strains of MSSA but nearly all MRSA
isolates are resistant. Nevertheless, first-generation
cephalosporins were not identified as a unique risk factor
for either organism in this study. The same holds true for
exposure to clindamycin. 
We think that these results support a third mechanism
that is independent of the specific antimicrobial agent
activity of the fluoroquinolones. Bisognano et al. have sug-
gested an alternative mechanism by which the fluoro-
quinolones could uniquely predispose to colonization (and
subsequent infection) with S. aureus. In a series of in vitro
experiments, these researchers have demonstrated that
exposure to subinhibitory levels of ciprofloxacin results in
increased expression of adherence factors promoting host
colonization. Isogenic S. aureus mutants expressing vary-
ing levels of fluoroquinolone resistance, when grown in
the absence of drug, showed little difference in adhesion
characteristics when compared with parental strains.
However, impressive changes in adhesion were exhibited
when strains were grown in the presence of 1/4 MIC of
ciprofloxacin. This increased adhesion, which was most
pronounced among highly resistant mutants, occurred at
therapeutically achievable concentrations of ciprofloxacin
and was associated with overexpression of fibronectin-
binding protein (25). In subsequent work with clinical
specimens, the same group showed that 8 of 10 MRSAiso-
lates and 4 of 6 MSSA isolates exhibited increased attach-
ment to fibronectin-coated surfaces after growth in the
presence of subinhibitory concentrations of ciprofloxacin.
Further, they demonstrated that the effect is mediated at
the level of transcription by activation of the fnb promoter
(26). More recently, the same group showed that the SOS
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Table 3. Results of univariate analysis for MSSA cases  
Risk factor  MSSA cases (n = 163) 
Demographic  No.  %  OR (95% CI)  p value 
Male  91  55.8  1.89 (1.29 to 2.77)  0.001 
Age  Mean = 63.3 y.       
<50  42  25.8  —  — 
51–75  68  41.7  1.50 (0.95 to 2.37)  0.08 
>75  53  32.5  2.10 (1.27 to 3.45)  0.004 
Coexisting condition           
Cardiovascular disease  117  71.8  2.08 (1.39 to 3.13)  <0.001 
Lung disease  61  37.4  2.95 (1.92 to 4.54)  <0.001 
Renal disease  28  17.2  2.06 (1.17 to 3.62)  0.01 
Hepatic disease  24  14.7  3.16 (1.64 to 6.10)  <0.001 
Organ transplant  2  1.2  1.00 (0.18 to 5.60)  0.99 
AIDS  1  0.6  0.39 (0.00 to 3.42)  0.40 
Malignancy  30  18.4  1.21 (0.74 to 1.98)  0.46 
Diabetes mellitus   38  23.3  1.25 (0.80 to 1.98)  0.33 
Hospital factors         
Transfer  29  17.8  2.11 (1.22 to 3.64)  0.01 
Surgical procedure  62  38.0  0.78 (0.52 to 1.15)  0.20 
ICU stay  89  54.6  6.38 (4.14 to 9.83)  <0.001 
Intravenous line  50  30.7  1.99 (1.28 to 3.09)  0.002 
Emergent admission  97  59.5  1.90 (1.30 to 2.79)  <0.001 
Admission service         
Medical  85  52.1  —  — 
Obstetrical  3  1.8  0.10 (0.03 to 0.34)  <0.001 
Surgical   75  46.0  1.49 (1.00 to 2.21)  0.05 
Antimicrobial drugs         
Any fluoroquinolone   37  22.7  0.96 (0.60 to 1.53)  0.86 
Levofloxacin  24  14.7  1.09 (0.62 to 1.90)  0.77 
Ciprofloxacin  14  8.6  0.74 (0.38 to 1.44)  0.37 
Vancomycin  31  19.0  1.78 (1.04 to 3.05)  0.36 
Penicillin  33  20.2  2.17 (1.28 to 3.66)  0.004 
β-lactam and inhibitor  6  3.7  2.37 (0.70 to 8.06)  0.17 
First-generation cephalosporin  27  16.6  0.65 (0.40 to 1.07)  0.09 
Third-generation cephalosporin  18  11.0  1.21 (0.64 to 2.30)  0.56 
Carbapenem  2  1.2  1.05 (0.17 to 6.48)  0.96 
Clindamycin  6  3.7  1.35 (0.47 to 3.91)  0.58 
Metronidazole  34  20.9  1.70 (1.02 to 2.83)  0.04 
a MSSA, methicillin-susceptible Staphylococcus aureus; OR, odds ratio; CI, confidence interval. RecA-mediated pathway, but not the agr or sar regulatory
elements, plays a role in the control of this phenomenon
(27,28). 
While the association between levofloxacin or
ciprofloxacin exposure and MRSA colonization could be
at least partially explained by the promotion of S. aureus
adherence, the present epidemiologic study suggests a
means by which the phenomenon would apply whether or
not the upregulation of fibronectin binding is a feature
unique to resistant isolates. Exposure to levofloxacin or
ciprofloxacin that promotes increased adherence of both
MRSAand MSSAwould have the net effect of increasing
the likelihood of recovery of fluoroquinolone-resistant
isolates. Because most MSSA isolates, as opposed to
MRSA, are susceptible to the fluoroquinolones (92% vs.
3% in this study), MSSA would be selectively eliminated
by the antimicrobial agent action of either drug before
colonization could be established. In summary, fluoro-
quinolone exposure would have the dual effect of promot-
ing S. aureus colonization while selectively eradicating
MSSA strains; the net effect of which is to favor MRSA
colonization.
In addition to the overall effect of the fluoroquinolones,
we also sought to examine the difference in risk associat-
ed with ciprofloxacin versus levofloxacin. Although we
observed a trend toward greater risk for MRSAafter expo-
sure to levofloxacin than ciprofloxacin, the difference was
not significant. Such a difference, if confirmed by further
investigation, would be unexpected. On the basis of com-
parative MIC data, levofloxacin is considered more active
than ciprofloxacin against susceptible isolates of S. aureus.
Our results indicate that levofloxacin may be more likely
to promote MRSA and suggest that the effect of lev-
ofloxacin in promoting colonization may be stronger than
that of ciprofloxacin. Any differences between fluoro-
quinolones, if proven, would have important implications
regarding the clinical decision to choose a particular fluo-
roquinolone and could shed light on the mechanism of the
relationship between these agents and MRSA. 
The association between fluoroquinolone exposure and
MRSA, established here using rigorous epidemiologic
methods, serves as a reminder that the risk factors associ-
ated with emerging antimicrobial resistance may not
always be predictable or intuitively obvious. Careful con-
sideration must be given to the clinical implications of
these findings. In the case of fluoroquinolones and MRSA,
decisions promoting the use of a single antimicrobial drug
or class of agents could have unforeseen effects on the
emergence of antimicrobial resistance.
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